z-logo
Premium
Cathepsin K expression in a wide spectrum of perivascular epithelioid cell neoplasms ( PEC omas): a clinicopathological study emphasizing extrarenal PEC omas
Author(s) -
Rao Qiu,
Cheng Liang,
Xia Qiuyuan,
Liu Biao,
Li Li,
Shi Qunli,
Shi Shanshan,
Yu Bo,
Zhang Rusong,
Ma Henghui,
Lu Zhenfeng,
Tu Pin,
Zhou Xiaojun
Publication year - 2013
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.12059
Subject(s) - pathology , cathepsin k , immunohistochemistry , biology , medicine , receptor , osteoclast
Aims Recent studies have demonstrated that cathepsin K seems to be a powerful marker in identifying renal perivascular epithelioid cell neoplasms ( PEC omas). However, the expression in extrarenal PEC omas has not been well characterized due to their rare incidence. Our aim was to investigate the expression of cathepsin K in a wide spectrum of extrar‐enal PEC omas and evaluate its potential diagnostic usefulness in comparison with other commonly used markers. Methods and results Twenty‐three cases of PEC oma (liver, n  =   9; lung, n  =   1; broad ligament of uterus, n  =   1; vertex subcutaneous soft tissue, n  =   1; abdominal wall, n  =   1; and kidney, n  =   10) were selected for study. All displayed a high percentage of cells with moderately to strongly positive reactions for cathepsin K (mean 91%; range 80–100%). HMB 45, Melan‐A and smooth muscle actin ( SMA ) were expressed in 78, 87 and 87% of cases, respectively, with various percentages of positive cells (mean, 34, 40 and 38%; range 0–80, 0–90 and 0–90%). Transcription factor E3 ( TFE 3) was expressed strongly in only three cases; none exhibited evidence of TFE3 gene fusion or amplification. Conclusions Cathepsin K appears to be more powerful than other commonly used markers in diagnosing a wide spectrum of PEC omas and distinguishing them from the majority of human cancers.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here